Rekombinanter NOTCH1 (Brontictuzumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter NOTCH1 (Brontictuzumab Biosimilar) Antikörper (ABIN7675801)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-NOTCH1 Reference Antibody (brontictuzumab)
-
Sequenz
- QVQLVQSGAE VKKPGASVKI SCKVSGYTLR GYWIEWVRQA PGKGLEWIGQ ILPGTGRTNY NEKFKGRVTM TADTSTDTAY MELSSLRSED TAVYYCARFD GNYGYYAMDY WGQGTTVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ TYTCNVDHKP SNTKVDKTVE RKCCVECPPC PAPPVAGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK,QAVVTQEPSL TVSPGGTVTL TCRSSTGAVT TSNYANWFQQ KPGQAPRTLI GGTNNRAPGV PARFSGSLLG GKAALTLSGA QPEDEAEYYC ALWYSNHWVF GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLVS DFYPGAVTVA WKADGSPVKV GVETTKPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCRVTH EGSTVEKTVA PAECS
-
Produktmerkmale
- Anti-NOTCH1 Reference Antibody (brontictuzumab) is expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG2SA
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Therapeutic Agents by Target and Mechanism: NOTCH1 inhibitors, immunity regulators
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- NOTCH1 (Brontictuzumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Molekulargewicht
- 145.5 kDa
-
UniProt
- P46531
Target
-